Dr. Turer is originally from Las Vegas, NV and received his medical and graduate training at the University of Chicago, Pritzker School of Medicine.  He arrived at UT Southwestern in 2009 as part of the Physician Scientist Training Program (PSTP), doing his internship, residency and fellowship here.  He focuses his clinical work on treating inflammatory bowel disease (IBD).  His research focus is on discovering new genes involved in maintaining intestinal homeostasis.


Medical School
University of Chicago Pritzker School of Medicine (2009)
UT Southwestern Medical Center (2011), Internal Medicine
UT Southwestern Medical Center (2015), Gastroenterology

Research Interest

  • Apoptotic and Inflammatory Signaling
  • Inflammatory Bowel Disease
  • Intestinal Epithelial Cell Biology
  • Mucosal Immunology


Featured Publications LegendFeatured Publications

Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme.
Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E, Agelidis A, Shifrin N, Advincula R, Barrera J, Malynn BA, Wu H, Ma A Immunity 2013 May 38 5 896-905
A potential novel use for direct antiviral therapy.
Turer E, Rockey DC, Singal AG Hepatology 2013 Jan 57 1 414-5
Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis.
Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A Nat. Immunol. 2011 Dec 12 12 1184-93
The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity.
Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, Ma A Immunity 2010 Aug 33 2 181-91
ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development.
Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, Shifrin N, Lee B, Benedict Yen TS, Yen B, Woo T, Malynn BA, Ma A Nature 2009 Feb 457 7231 906-9
The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals.
Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, Werts C, Ma A Immunity 2008 Mar 28 3 381-90
Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20.
Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, Lee B, Shifrin N, Malynn BA, Ma A J. Exp. Med. 2008 Feb 205 2 451-64
E2 enzymes: expanding the 'ubi-verse' of immune signaling.
Ma A, Turer E Nat. Immunol. 2006 Sep 7 9 903-4
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.
Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, Ma A Nat. Immunol. 2004 Oct 5 10 1052-60

Honors & Awards

  • President's Research Council Award
    UTSW (2017)
  • Fellow Research Award
    Crohn's and Colitis Foundation of America (2014)
  • Keystone Scholar Award
    Keystone Symposium (2005)
  • UCLA Merck Index Award for Outstanding Achievement in Undergraduate Chemistry
    University of California, Los Angeles (2000)